GlassScriptPhysician profile
Ann Lu Jenkins
NPI 1528300787
$1,314.81
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $155 · 2021: $551 · 2022: $57.85 · 2023: $30.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $30.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $30.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.67 | 2019-2022 | |
| Exeltis, USA INC. | $76.96 | 2021 | |
| Hologic Sales and Service, LLC | $76.66 | 2019-2023 | Coolseal Generator |
| Coopersurgical, INC. | $76.44 | 2019-2021 | |
| Allergan, INC. | $74.69 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.61 | 2019-2020 | |
| Organon LLC | $59.96 | 2021-2022 | |
| Agile Therapeutics, INC. | $51.09 | 2021 | |
| Lupin INC. | $47.52 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $45.78 | 2019-2021 | |
| Astellas Pharma US INC | $41.69 | 2019 | |
| Millicent US INC | $33.64 | 2019-2020 | |
| Renovia INC | $33.22 | 2019-2020 | |
| Medicem INC. | $31.29 | 2020-2021 | |
| Myovant Sciences INC. | $23.70 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $19.14 | 2019 | |
| Therapeuticsmd, INC. | $16.46 | 2019 | |
| Pfizer INC. | $15.00 | 2021 | |
| Mylan Pharmaceuticals INC. | $14.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Jenkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.